Search ARM

Rigenerand aims to develop and produce cGMP products for cell-based therapies and tailored biomedical devices for preclinical and clinical applications.
First therapy to be introduce in phase I/II is a product based on human adipose perivascular stromal cells genetically modified to secrete soluble necrosis factor-related apoptosis-inducing ligand (AD-PC-sTRAIL)

Contact Rigenerand
Visit Website